statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex ), an innovative revenue-generating company focused on acquiring, developing and commercializing...

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue-generating company focused on acquiring, developing and...

Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

Seek approval from the FDA for the modification of the Gloperba label to include its ability to utilize dosing flexibility of liquid formulation to address unmet medical needs and provide specific...

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba  Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue-generating company focused on acquiring, developing and...

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici

PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex ), an innovative revenue-generating company focused on acquiring, developing and commercializing...

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it...

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB  Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB  for Acute Treatment of Migraine With or Without Aura in 

The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex's innovative FDA approved non-opioid therapies and pipeline candidate...

Scilex Holding Announces Issuance of Halal Certification for its ZTlido  product by Circle H International, Inc.

PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue generating company focused on acquiring, developing and...

Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Su

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or the Company ), an innovative revenue-generating company focused on acquiring, developing and...

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

Gloperba is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba , its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the Fir

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Watchers	2,361
52-Wk Low	$0.7316
52-Wk High	$8.30

Volume	1.00
52-Wk High	$8.30
52-Wk Low	$0.7316

SCLX Scilex Holding Company

About

Feed

News

Sentiment

Earnings

Fundamentals